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http://dx.doi.org/10.1016/j.ccr.2012.06.005SUMMARYGenomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic leukemia (B-ALL)
with alteration of IKZF1, a gene expression profile similar to BCR-ABL1-positive ALL and poor outcome
(Ph-like ALL). The genetic alterations that activate kinase signaling in Ph-like ALL are poorly understood.
We performed transcriptome and whole genome sequencing on 15 cases of Ph-like ALL and identifiedSignificance
Ph-like ALL patients comprise up to 15% of childhood ALL, exhibit a high risk of relapse and have a poor outcome. Using
next-generation sequencing, we have shown that genetic alterations activating kinase or cytokine receptor signaling are
a hallmark of this subtype and that a number of these lesions are sensitive to tyrosine kinase inhibitors (TKIs). Thus, our find-
ings support screening at diagnosis to identify Ph-like ALL patients that may benefit from the addition of TKI treatment to
current chemotherapeutic regimens. Furthermore, this study illustrates how genomic analysis can be used to drive tailored
therapy for cancer patients.
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Kinase-Activating Alterations in High-Risk ALLrearrangements involving ABL1, JAK2, PDGFRB, CRLF2, and EPOR, activating mutations of IL7R and FLT3,
and deletion of SH2B3, which encodes the JAK2-negative regulator LNK. Importantly, several of these alter-
ations induce transformation that is attenuated with tyrosine kinase inhibitors, suggesting the treatment
outcome of these patients may be improved with targeted therapy.INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common pedi-
atric malignancy, and relapsed B-lineage ALL remains a leading
cause of cancer death in young people (Pui et al., 2008).
B-progenitor acute lymphoblastic leukemia (B-ALL) is charac-
terized by recurring chromosomal abnormalities, including aneu-
ploidy, chromosomal rearrangements (e.g., ETV6-RUNX1, BCR-
ABL1, and TCF3-PBX1), and rearrangements ofMLL andCRLF2
(Pui et al., 2008; Mullighan et al., 2009a; Russell et al., 2009a;
Harvey et al., 2010a; Yoda et al., 2010). However, leukemic cells
from many patients with relapsed B-ALL lack known chromo-
somal alterations. Therefore, identifying the full repertoire of
genetic lesions in high-risk ALL is essential to improve the treat-
ment outcome of this disease.
Genome-wide analyses have identified genetic alterations
targeting transcriptional regulators of lymphoid development
(PAX5, EBF1, and IKZF1) in over 60% of B-ALL patients (Kuiper
et al., 2007; Mullighan et al., 2007, 2009b). IZKF1 alteration is
a hallmark of Philadelphia chromosome (Ph+) ALL with BCR-
ABL1 fusion (Mullighan et al., 2008; Iacobucci et al., 2009) and
is also associated with poor outcome in both BCR-ABL1-
positive and BCR-ABL1-negative ALL (Den Boer et al., 2009;
Martinelli et al., 2009; Mullighan et al., 2009b). Notably, IKZF1-
mutated, BCR-ABL1-negative cases commonly exhibit a gene
expression profile similar to BCR-ABL1-positive ALL, and these
cases are referred to as ‘‘Ph-like ALL’’ (Den Boer et al., 2009;
Mullighan et al., 2009b). Ph-like ALL comprises up to 15% of
pediatric B-ALL, and these patients have a higher risk of
relapse compared to other BCR-ABL1-negative patients, with
5-year event-free survival rates of 63% and 86%, respectively
(our unpublished data). Approximately 50% of Ph-like patients
harbor rearrangements of CRLF2 (CRLF2r) (Harvey et al.,
2010a), with concomitant Janus kinase (JAK) mutations de-
tected in approximately 50% of CRLF2r cases (Mullighan et al.,
2009a; Russell et al., 2009a; Harvey et al., 2010a; Yoda et al.,
2010). However, the genetic alterations responsible for activated
kinase signaling in the remaining Ph-like cases are unknown.
To identify the genetic basis of this subtype, we performed
transcriptome and whole genome sequencing on tumor and
matched normal material from 15 patients with Ph-like ALL.
RESULTS
Chromosomal Rearrangements in Ph-like ALL
To identify genetic alterations in Ph-like ALL, we performed
paired-end messenger RNA sequencing (mRNA-seq) on 15
B-ALL cases that were identified as Ph-like using prediction
analysis of microarrays (PAM; Table 1; Table S1 available online)
(Tibshirani et al., 2002) and Recognition of Outliers by Sampling
Ends (ROSE) (Harvey et al., 2010b). Importantly, the gene
expression profile of Ph-like ALL determined by limma (Linear
Models for Microarray Analysis; Table S2) (Smyth, 2004) ex-154 Cancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc.hibited highly significant enrichment for the previously described
signature of high-risk, IKZF1-deleted ALL (Mullighan et al.,
2009b) (data not shown). Whole genome sequencing (WGS) of
tumor DNA was also performed for two cases lacking kinase-
activating rearrangements on analysis of mRNA-seq data. We
used multiple complementary analysis pipelines, including
deFuse (McPherson et al., 2011), Mosaik (Marth, 2010), CREST
(Wang et al., 2011), CONSERTING (Zhang et al., 2012), and
Trans-ABySS (Robertson et al., 2010) to identify rearrange-
ments, structural variations, and sequence mutations. Putative
somatic sequence variants were identified by comparing tumor
data to WGS data of matched normal DNA and were validated
using orthogonal sequencing methods. Overviews of method-
ology and findings are provided in Figure 1 and Figure S1.
Strikingly, we identified alteration of genes encoding cytokine
receptors and regulators of kinase signaling in all 15 cases
studied (Table 1). Putative rearrangements were validated by
reverse transcription followed by polymerase chain reaction
(RT-PCR) and Sanger sequencing (Figure 2), with an average of
1.9 rearrangements identified per case (range 0–5; Table S3
and Figure S2). The rearrangements included two cases with
NUP214-ABL1, one case with insertion of the erythropoietin
receptor gene (EPOR) into the immunoglobulin heavy chain locus
(IGH@-EPOR), and one case each with the in-frame fusions
EBF1-PDGFRB, BCR-JAK2, STRN3-JAK2, PAX5-JAK2, ETV6-
ABL1, RANBP2-ABL1, and RCSD1-ABL1. These rearrange-
ments were either cryptic on cytogenetic analysis or the fusion
partners could not be identified on examination of karyotypic
data alone (Table 1). In each case multiple paired-end reads
mapped to the partner genes, and split reads mapping across
the fusion were identified (Figure 3A and Figure S3A). Additional
putative fusion transcripts were identified for each case (Fig-
ure S2 and Table S3); however, these commonly showed a
low level of read support, did not encode an open-reading
frame (SEMA6A-FEM1C, OAZ1-KLF2, and ZNF292-SYNCRIP),
or involved intronic fusion break points (DOCK8-CBWD2 and
TSHZ2-SLC35A1), suggesting they do not contribute to leuke-
mogenesis. We also identified an inversion involving PAX5 and
the adjacent gene ZCCHC7, resulting in a reciprocal fusion that
disrupts the open reading frame of PAX5 (Figure S2H). Deletions,
translocations, and sequence mutations of PAX5 are detected in
approximately 30% of B-ALL patients (Mullighan et al., 2007),
and this inversion represents another mechanism for PAX5
inactivation.
CRLF2 is overexpressed in up to 7% of B-ALL, including over
50% of ALL cases in children with Down syndrome, and occurs
via multiple mechanisms involving either a cryptic translocation
that juxtaposes CRLF2 to the regulatory elements of the immu-
noglobulin heavy chain locus (IGH@-CRLF2) (Mullighan et al.,
2009a; Russell et al., 2009a) or an interstitial deletion of the
pseudoautosomal region one (PAR1) centromeric to CRLF2
resulting in the P2RY8-CRLF2 rearrangement (Mullighan et al.,
2009a). Less frequently, the point mutation affecting codon
Table 1. Chromosomal Rearrangements Detected in High-Risk B-Lineage ALL
Sample ID Cohort Rearrangement Sex
Age
(Years) WCC 3 109/l Key Lesions Karyotype
PAKTAL P9906 STRN3-JAK2a Female 12.2 478 IKZF1 deletion and
p.Leu117fs mutation
N/A
PAKKCA P9906 EBF1-PDGFRBa Male 11.7 236.4 IKZF1 (IK6); EBF1 deletion; PAX5
inversiona; CDKN2A/CDKN2B
deletion
46,XY,del(6)(q13q23),del(9)
(p22)[20]
PAKVKK P9906 NUP214-ABL1a Male 14.4 220.7 IKZF1 p.Ser402fs mutation; PAX5
deletion; CDKN2A/CDKN2B
deletion
N/A
PALIBN P9906 IGH@-EPORa Male 14.3 29.9 IKZF1 e1-5 deletion;
CDKN2A/CDKN2B deletion
N/A
PAKYEP P9906 BCR-JAK2a Male 2.7 958.8 IKZF1 (IK6); EBF1 deletion; PAX5
deletion and p.Gly24Arg mutation;
CDKN2A/CDKN2B deletion
47,XY,+2,del(2)(p23),t(3;22;9)
(p12;q11.2;p24) [10]/46,XY[2]
PAMDRM P9906 IGH@-CRLF2b Male 7.9 351.3 JAK2 p.Ile682_Arg683insGlyProa;
IKZF1 deletion e1-e6; EBF1
deletion; PAX5 p.Val319fs;
CDKN2A/CDKN2B deletion
46,XY[20]
PAKKXB P9906 IGH@-CRLF2b Female 14.5 92.7 IKZF1 (IK6); CDKN2A/CDKN2B
deletion; FLT3 p.Asn609ins23aac
46,XX[21]
PALETF P9906 None Female 7.6 105.7 EBF1 deletion; FLT3
p.Leu604ins23aaa
47,XX,+10[3]/46,XX,+10,
21[7]/46,XX[8]
PAKHZT P9906 IGH@-CRLF2b Male 13.9 307 JAK2 p.Arg867Gln;
CDKN2A/CDKN2B deletion
N/A
PALJDL P9906 None Male 3.2 156 PAX5 deletion; CDKN2A/CDKN2B
deletion; IL7R
p.L242_L243insFPGVC mutationd;
SH2B3 e1–2 deletiond
N/A
PANNGL AALL0232 PAX5-JAK2a Female 12.9 15.8 IKZF1 deletion 47,XX,r(7)(p12q31),+9[14]/
46,XX[6]
PANSFD AALL0232 ETV6-ABL1a Male 5.4 83 IKZF1 (IK6); PAX5 deletion;
CDKN2A/CDKN2B deletion
46,XY,ins(12;9)(p13;
q34q34)[20]
PANEHF AALL0232 RCSD1-ABL1a Male 15.7 47.8 N/A N/A
SJBALL085 Total XV NUP214-ABL1a Male 16.3 135.6 IKZF1 (IK6) and p.Ala79fs mutationa 46,XY
SJBALL010 Total XVI RANBP2-ABL1a Male 15 121 PAX5 deletiona 46,XY,t(2;9)(q21;q34)[14]/
46, XY[6]
Chromosomal rearrangements affecting kinase and cytokine receptor signaling identified bymRNA-seq in 15 Ph-like cases. Genetic lesions disrupting
B cell development (IKZF1, EBF1, and PAX5) and JAK2-activating mutations are also shown. IK6 refers to the deletion of IKZF1 exons 4–7 (coding
exons 3–6), which results in the expression of a dominant negative IKZF1 isoform that lacks the N-terminal DNA-binding zinc fingers. All cases
were of B-precursor immunophenotype and did not exhibit expression of T-lineage markers. Frame shifts (fs) are designated using the short nomen-
clature as outlined by the Human Genome Variation Society. aa, amino acid; e, exon; ITD, internal tandem duplication; N/A, not available; WCC, white
cell count (3 109/l).
aIdentified by RNA-seq analysis.
bPreviously known (Harvey et al., 2010a).
cPreviously known (Zhang et al., 2011).
dIdentified by whole genome sequencing. See Tables S1, S2, S3, S4, S5, S6, S7, S8, and S9.
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Kinase-Activating Alterations in High-Risk ALL232 (p.Phe232Cys) has also been identified (Yoda et al., 2010;
Chapiro et al., 2010). Mutations activating JAK are present in
approximately 50% of CRLF2r cases (Mullighan et al., 2009a;
Russell et al., 2009a; Harvey et al., 2010a; Hertzberg et al.,
2010; Yoda et al., 2010); however, the nature of kinase-activating
mutations in CRLF2r cases lacking JAK mutations is unknown.
Three cases in the discovery cohort were known to have the
IGH@-CRLF2 translocation, and one of these harbored a known
JAK2mutation (p.Arg867Gln) (Mullighan et al., 2009c). Two addi-tional CRLF2r cases lacking known JAK mutations were
sequenced, one of which harbored a FLT3 internal tandem dupli-
cation (ITD; p.Asn609ins23aa) (Zhang et al., 2011), and the other
harbored a complex JAK2 mutation (p.Ile682_Arg683insGlyPro
in case PAMDRM) that was not identified by previous Sanger
sequencing (Mullighan et al., 2009c). No additional kinase-acti-
vating lesions were identified in the CRLF2r cases. A full listing
of somatic single nucleotide variants (SNVs) and insertions/dele-
tions identified by mRNA-seq are provided in Table S4.Cancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc. 155
Figure 1. Flow Chart of Methodology
(A) Fifteen Ph-like high-risk (HR) ALL cases were
subjected to mRNA-seq, with matched normal
DNA subjected to whole genome sequencing
(WGS). Two cases also had WGS of tumor DNA.
(B) For recurrence testing of ABL1, JAK2, and
PDGFRB fusions, cases with available RNA from
AALL0232 were screened by RT-PCR. The two
NUP214-ABL1 cases identified in P9906 showed
gain of 9q34 between NUP214 and ABL1 on SNP
array analysis, and the presence ofNUP214-ABL1
was confirmed by RT-PCR. Whole genome
amplified (WGA) leukemic DNA was used for
recurrence of IL7R and SH2B3 mutations. FLT3
mutations were reported previously (Zhang et al.,
2011).
See also Figure S1.
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PDGFRB fusion that was present in the predominant leukemic
clone, as confirmed by fluorescence in situ hybridization (FISH)
(Figure S3). mRNA-seq coverage analysis for this case showed
a sharp increase in read depth at intron 10 of PDGFRB that
corresponds to the genomic break point (Figure 3B). Both genes
are located on chromosome 5q, and analysis of DNA copy
number data revealed a deletion between the two break points
(Figure 3C). Genomic PCR identified the break point 0.5 kb
downstream of EBF1 exon 15 and 2.3 kb upstream of PDGFRB
exon 11 in the index case (Figure 3D). Several copy number
alterations and rearrangements in B-ALL arise from aberrant
recombination-activating gene (RAG) activity (Mullighan et al.,
2007, 2009a); however, analysis of the sequences adjacent to
the genomic break points of EBF1 and PDGFRB showed no
evidence of RAG-mediated activity in this case.
The NUP214-ABL1 rearrangement has not previously been
reported in B-ALL but is present in 5% of T-lineage ALL and
commonly accompanies episomal amplification of 9q34 (Graux
et al., 2004). Notably, both NUP214-ABL1 cases had pre-B-
ALL immunophenotype with no expression of T-lineagemarkers,
and in contrast to T-ALL, did not show high-level episomal
amplification by FISH analysis (data not shown). Instead, we
observed gain of only one copy of DNA between the two partner
genes at 9q34 (Figure S2I). The ABL1 break points correspond
to those observed in NUP214-ABL1 T-ALL (De Braekeleer
et al., 2011) and Ph+ chronic myeloid leukemia or B-ALL (Melo,
1996), which retain the SH2, SH3, and kinase domains of ABL1.
Case PAKYEP harbored the BCR-JAK2 fusion, which has
previously been identified in myeloid leukemia (Griesinger
et al., 2005; Cirmena et al., 2008) but not in B-ALL. Visualization
of mRNA-seq split-reads using Bambino (Edmonson et al., 2011)
identified two BCR-JAK2 fusion transcripts in this case involving
exon 1 of BCR fused to either exon 15 or 17 of JAK2, both of
which were validated by RT-PCR and sequencing (Figure S4A).156 Cancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc.Using Bambino, we also mapped the
genomic break point at intron 1 of BCR,
located within the minor break point
cluster region, to intron 14 of JAK2 (Fig-
ure S4B). Notably, all JAK2 fusions
identified in this study are in-frame anddisrupt the pseudokinase domain of JAK2, which is thought to
relieve autoinhibition of the kinase domain, thus resulting in a
constitutively active fusion protein.
The IGH@-EPOR rearrangement arising from a reciprocal
t(14;19)(q32;p13) translocation has been documented in B cell
precursor ALL (Russell et al., 2009b). However, FISH for the
t(14;19) rearrangement in case PALIBN was negative. Detailed
analysis of mRNA-seq data and genomic mapping demon-
strated that the rearrangement involved a 7.5 kb insertion of
EPOR into the immunoglobulin heavy chain locus downstream
of the IgH enhancer domain with similar cytogenetic break
points as the previously identified translocation, thus identifying
another mechanism of IGH@-EPOR rearrangement (Figure 4).
Sequence Mutations and Deletions in Ph-like ALL
WGS of tumor and normal DNA was performed on two Ph-like
cases for which a kinase-activating rearrangement was not
identified by mRNA-seq. Case PALJDL harbored two alterations
predicted to activate tyrosine kinase signaling, the first being an
in-frame insertion in the transmembrane domain of the inter-
leukin 7 receptor, IL7R (p.Leu242_Leu243insFPGVC; Figure 5A).
Using the mRNA-seq mutant allele read counts, we estimated
the IL7R mutation to be expressed in approximately 93.4% of
cells in the sample sequenced. Similar activating mutations in
IL7R have recently been described in pediatric B and T-lineage
ALL (Shochat et al., 2011; Zenatti et al., 2011; Zhang et al.,
2012). Interestingly, case PALJDL also harbored a focal homozy-
gous deletion removing the first two exons of SH2B3 that was
not evident by SNP array analysis, with a concomitant absence
of SH2B3 expression by mRNA-seq analysis (Figures 5B and
5C). By comparing the coverage in the region of homozygous
deletion (1.153) to that of the undeleted region downstream on
the same chromosome (30.863), we estimate this deletion to
be in at least 96% of cells in the sample sequenced. SH2B3
encodes the protein LNK, which is a negative regulator of
Figure 2. Rearrangements in Ph-like ALL
(A) Predicted domain structure of the in-frame fusions EBF1-PDGFRB (E/P), BCR-JAK2 (B/J), STRN3-JAK2 (S/J), PAX5-JAK2 (P/J), NUP214-ABL1 (N/A), ETV6-
ABL1 (E/A), RANBP2-ABL1 (R/A), and RCSD1-ABL1 (RC/A) identified by mRNA-seq in eight Ph-like ALL cases. Confirmation of predicted fusions by RT-PCR (B)
and Sanger sequencing (C). The two bands for BCR-JAK2 correspond to two different fusion break points within JAK2 (exon 15 and 17), both of which were
confirmed by Sanger sequencing. IPT/TIG, immunoglobulin-like fold, plexins, transcription factors/transcription factor immunoglobulin; FG, phenylalanine and
glycine; SH, Src homology domain.
See also Figure S2.
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Figure 3. mRNA-seq Data, Recurrence
Screening, and Genomic Mapping of the
EBF1-PDGFRB Fusion
(A) Split readsmapping across the EBF1-PDGFRB
fusion point for case PAKKCA. Amino acid sub-
stitution from wild-type PDGFRB (Ser > Ala) is
highlighted in green.
(B) Coverage depth for all mRNA-seq reads at
the EBF1 and PDGFRB locus in case PAKKCA,
showing expression across the EBF1 locus and
increased expression of PDGFRB at intron 10
(arrowed). The vertical height of the red bar indi-
cates the number of reads covering the site.
(C) SNP 6.0 microarray log2 ratio DNA copy
number heatmap showing deletion (blue) between
EBF1 and PDGFRB for two EBF1-PDGFRB cases
(PANJJE and PANNKX) and four non-rearranged
cases with focal EBF1 deletions (left).
(D) Genomic mapping of the EBF1-PDGFRB
rearrangement break point by PCR (top) and
sequencing (bottom), showing juxtaposition of
EBF1 intron 15 (chr5:158067136) to PDGFRB
intron 10 (chr5:149488649), with the addition of
nontemplate nucleotides between the break
points.
(E) RT-PCR confirmation of EBF1-PDGFRB fusion
in four high-risk B-ALL cases with exon 14 (bottom
band) or exon 15 (top band) of EBF1 fused to exon
11 of PDGFRB.
See also Figure S3.
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within exon 2 have been identified in JAK2 p.Val617Phe-negative
myeloproliferative neoplasms (MPN) (Oh et al., 2010; Pardanani
et al., 2010) and early T cell precursor ALL (Zhang et al., 2012).
Case PALETF was found to harbor an in-frame ITD within
the FLT3 juxtamembrane domain (p.Leu604ins23aa; Table S4).
FLT3 ITDs and increased expression of wild-type FLT3 are also
present in high-risk acute myeloid and lymphoblastic leukemia
(Schnittger et al., 2002; Armstrong et al., 2003; Paietta et al.,
2004; Zhang et al., 2012). Similar to PDGFRB and JAK2 rear-
rangements, FLT3 mutations facilitate leukemic transformation
by inducing constitutive kinase activation and signaling through
the Ras and JAK/STAT5 pathways (Mizuki et al., 2000). Addi-
tional SNVs and structural variations identified by WGS of
PALJDL and PALETF are provided in Tables S5, S6 and, S7
and Figure S5.
Recurrence of Genetic Alterations in Ph-like B-ALL
We next performed recurrence screening of extended cohorts
of high-risk B-ALL to determine the frequency of these
genetic alterations (Figure 1). RT-PCR for the EBF1-PDGFRB,158 Cancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc.BCR-JAK2, STRN3-JAK2, PAX5-JAK2,
NUP214-ABL1, ETV6-ABL1, RANBP2-
ABL1, and RCSD1-ABL1 fusions was
performed for 231 cases from a separate
consecutively recruited cohort of high-
risk B-progenitor ALL obtained from
the Children’s Oncology Group (COG)
AALL0232 study. Screening for these
fusions in the COG P9906 discoverycohort was not possible because of a lack of RNA for many
cases.We investigated the presence of IL7R andSH2B3 variants
in both the P9906 and AALL0232 cohorts by Sanger sequencing
of tumor DNA and SNP array analysis of tumor and matched
nontumor DNA. CRLF2 rearrangements, JAK mutations and
amplification between NUP214 and ABL1 were examined in
both P9906 and AALL0232 cohorts by SNP array analysis,
genomic PCR and sequencing, and FISH for cases with 9q34
amplification. We also performed RT-PCR for the fusions and
genomic sequencing for IL7R in other hematopoietic malignan-
cies, including 23 MPN cases lacking JAK2 or MPL mutations,
25 chronic myelomonocytic leukemia (CMML) cases and 44
childhood acute myeloid leukemia (AML) cases, including 34
that lacked recurring chromosomal rearrangements.
Forty of 231 cases (14%) of the AALL0232 cohort were identi-
fied as Ph-like (Table S8). Twenty-five cases (8.8%) had high
CRLF2 expression, 19 of which were Ph-like and 6 non-Ph-
like. JAK mutations were present in ten cases with high CRLF2
expression, all of which were Ph-like (Table S9). The EBF1-
PDGFRB fusion was detected in three additional Ph-like patients
(8% of Ph-like ALL), in which exon 15 (n = 2) or exon 14 (n = 1) of
Cancer Cell
Kinase-Activating Alterations in High-Risk ALLEBF1 was fused to exon 11 of PDGFRB (Figure 3E). Each of the
EBF1-PDGFRB cases showed an increase in PDGFRB expres-
sion by gene expression profiling and two of these patients
(PANJJE and PANNKX) had an interstitial deletion between the
partner gene break points (Figure 3C).
No additional cases with the ABL1 or JAK2 rearrangements
identified in the discovery cohort were observed in the
AALL0232 cohort. Analysis of SNP array data identified two
cases in P9906 (PAMBWU and PALFBA, one Ph-like) with
a single copy gain of DNAbetweenNUP214 andABL1 (Figure 2I).
The presence of the NUP214-ABL1 rearrangement was con-
firmed by RT-PCR and Sanger sequencing (Figure 2J), indicating
that this fusion is also recurrent in B-ALL. No ABL1, JAK2, or
PDGFRB rearrangements were identified in the MPN, CMML,
and AML cohorts and have not been detected in other childhood
B-ALL subtypes studied by WGS and mRNA-seq (Downing
et al., 2012), indicating these genetic lesions are highly enriched
in the Ph-like subtype.
Mutations within the transmembrane domain of IL7R were
found in eight additional cases from P9906, five of which were
Ph-like (12.5% of Ph-like ALL) (Figure 5A). An additional Ph-like
case from the AALL0232 cohort (PANKMB) had a focal homo-
zygous deletion removing exons 1–2 of SH2B3 that was identi-
fied using the higher resolution SNP 6.0 microarray, and subse-
quently confirmed by PCR (data not shown). Interestingly, this
case harbors a P2RY8-CRLF2 rearrangement but lacks a JAK
mutation, suggesting that removal of JAK2 regulation by LNK
augments JAK signaling in this case. No additional somatic
SH2B3 mutations or deletions were identified in this study.
Sanger sequencing of FLT3 in the P9906 cohort reported muta-
tions in 12 cases, 4 of which were Ph-like (Table S9) (Zhang et al.,
2011).
Rearrangements Are Transforming and Sensitive to
Tyrosine Kinase Inhibitors
Recent phosphoflow cytometry studies have shown that B-ALL
leukemic cells harboring CRLF2 rearrangements (with or without
concomitant JAK mutations) have enhanced signaling through
oncogenic pathways that can be targeted with JAK or PI3K
inhibitors (Tasian et al., 2012). To determine if the genetic alter-
ations we identified in Ph-like ALL activate kinase signaling
and respond to TKIs, we performed flow cytometric phos-
phosignaling analysis on four primary leukemic samples (two
cases with the NUP214-ABL1 fusion, one case with the BCR-
JAK2 fusion, and one case with the STRN3-JAK2 fusion). All
cases demonstrated activation of downstream signaling path-
ways, with phosphorylation of the ABL1 substrate CRKL in the
NUP214-ABL1 cases and tyrosine phosphorylation in the cases
with BCR-JAK2 and STRN3-JAK2 fusions (Figure 6). Impor-
tantly, this basal level of phosphorylation was reduced with ima-
tinib, dasatinib, and XL228 in samples harboring the ABL1
fusion, and the JAK2 inhibitor, XL019, in the JAK2-rearranged
samples (Figure 6). Notably, XL019 had no effect on CRKL
phosphorylation in ABL1-positive cases; however, we did
observe slight inhibition of tyrosine phosphorylation with dasati-
nib in the JAK2-cases. Five non-Ph-like B-ALL cases were also
assessed by phosphoflow and showed minimal activation of
signaling pathways compared to Ph-like ALL, with no response
to ABL1 or JAK2 inhibitors (Figure S6).To evaluate the transforming potential of the EBF1-PDGFRB
fusion, we assessed the ability of murine Ba/F3 and Arf/
pre-B cells (Williams et al., 2006) expressing EBF1-PDGFRB
to proliferate in the absence of exogenous cytokines. EBF1-
PDGFRB expression (Figure 7A) conferred growth factor inde-
pendence and resulted in significantly faster proliferation com-
pared to Ba/F3 cells expressing the most common PDGFRB
rearrangement, ETV6-PDGFRB (Figures 7B and 7C). Impor-
tantly, cytokine-independent proliferation was inhibited by
imatinib (Figures 7B and 7C) and the multikinase inhibitors
dasatinib and dovitinib (Figure S7A). Accordingly, imatinib treat-
ment reduced phosphorylation of the PDGFRB receptor, with no
change in total PDGFRB expression (Figure S7B). Several onco-
genic pathways were constitutively activated by EBF1-PDGFRB
in pre-B cells, demonstrated by elevated levels of pSTAT5,
pAKT, and pERK1/2. Notably, this signaling was also inhibited
with dasatinib (Figures 7B, 7C, and S7C). In addition, we also
have evidence of a patient with EBF1-PDGFRB+ B-ALL refrac-
tory to induction chemotherapy entering remission with the
addition of imatinib (data not shown).
We next investigated the therapeutic efficacy of the JAK2
inhibitor, ruxolitinib, in a xenograft model of BCR-JAK2-rear-
ranged ALL (case PAKYEP). In this model cryopreserved BCR-
JAK2+ cells were injected into NOD.Cg-Prkdcscid l2rgtm1Wjl/Szj
(NSG) mice, and continuous infusion of ruxolitinib or vehicle
was commenced once engraftment exceeded 5% of peripheral
blood leukocytes (determined by measuring human CD19+/45+
cells). The presence of the fusion in xenografted cells was
confirmed by RT-PCR (data not shown). We observed a striking
decrease in leukemic burden after 4 weeks of ruxolitinib treat-
ment compared to vehicle-treated controls, as measured by
reduced peripheral blood (p < 0.001; Figure 7D) and spleen
blast counts (data not shown). Furthermore, a xenograft model
of NUP214-ABL1 ALL responded to dasatinib up to 8 weeks
of treatment (Figure 7D), confirming that cells expressing
NUP214-ABL1 are sensitive to TKIs (Quinta´s-Cardama et al.,
2008; Deenik et al., 2009). In addition, ruxolitinib significantly
decreased peripheral blood and spleen blast counts in a xeno-
graft model of case PALJDL, which harbors both an IL7R
activating mutation and a somatic SH2B3 (LNK) deletion (data
not shown). Together, these data indicate that EBF1-PDGFRB,
BCR-JAK2, andNUP214-ABL1 fusions and sequencemutations
in IL7R/SH2B3 are transforming, and represent excellent candi-
dates for therapy with currently available TKIs.
DISCUSSION
Ph-like ALL represents approximately 10% of childhood B-ALL
and 15% of high-risk B-ALL and is three to four times more
common than Ph+ ALL. Among a large cohort of patients with
high-risk B-ALL treated on COG AALL0232, the Ph-like pheno-
type is associated with older age (12.4 versus 9.5 years, p <
0.0001) and significantly inferior 5-year event-free survival
compared to non-Ph-like patients (our unpublished data).
Using next-generation sequencing, we have shown that rear-
rangements and sequence mutations activating tyrosine kinase
and cytokine receptor signaling are a hallmark of Ph-like
ALL. Moreover, each of the cases studied harbored genomic
lesions affecting lymphoid transcription factors (most commonlyCancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc. 159
Figure 4. Schematic of the IGH@-EPOR Rearrangement
(A) Plot of read depth obtained frommRNA-seq data showing increased read depth across the EPOR locus. The arrows correspond to the genomic break points
identified by genomic PCR and sequencing.
(B) Bambino viewer of mRNA-seq reads showing IGHJ5 with 40 bp of inserted sequence joined to 1.3 kb upstream of EPOR 50 untranslated region (UTR) on
chromosome 19. Bottom view shows split reads spanning exon 8 of EPOR adjacent to IGHV4.
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Figure 5. IL7R-Activating Mutations and
SH2B3 Deletion
(A) Protein domain structure of IL7R with location
of sequence mutations identified in the trans-
membrane domain of nine B-ALL cases.
(B) Copy number variant analysis of PALDJL
comparing tumor and matched nontumor DNA at
the SH2B3 locus.
(C) Transcript read depth data from mRNA-seq
analysis comparing three cases with normal
expression of SH2B3 to PALJDL. The vertical
height of the red bar indicates the number of
reads covering the site.
(D) Sanger sequencing confirming the deletion
from chr12:110325422 (first arrow) to chr12:
110361365 (second arrow).
See also Figure S5.
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tion of these two pathways cooperate to induce B-lineage ALL
and drive the Ph-like gene expression profile.
Chromosomal rearrangements resulting in activated tyrosine
kinase signaling are recognized as driver lesions in a number of
hematopoietic malignancies, the prototype being BCR-ABL1 in
CML (Melo, 1996) and Ph+ B-ALL (De Braekeleer et al., 2011).
Here, we report five fusions that, to our knowledge, have not
been reported in B-ALL (EBF1-PDGFRB, NUP214-ABL1, BCR-
JAK2, STRN3-JAK2, and RANBP2-ABL1) and several that
have been reported in very few patients, including IGH@-EPOR
(Russell et al., 2009b), PAX5-JAK2 (Nebral et al., 2009), ETV6-
ABL1, and RCSD1-ABL1 (De Braekeleer et al., 2011).(C) IGH@ contains an IGHM domain, enhancer (En), J domains (J1–J6) and the downstream IGHV4 gene seg
adjacent to the J5 domain and the 30 end is within the IGHV4 gene segment.
(D) Sanger sequencing confirming the rearrangement at IGHJ5 (chr14:105401115) to nontemplate sequence (l
(chr14:105549154).
See also Figure S4.
Cancer Cell 22, 153–166Rearrangements involving thePDGFRB
receptor are present at low frequency
in Ph-negative myeloid neoplasms (Go-
lub et al., 1994; Cross and Reiter,
2008). The identification of a PDGFRB
fusion is of clinical importance, as
patients with chronic myeloproliferative
disease and activating PDGFRB rear-
rangements show complete hemato-
logic and molecular responses to imati-
nib treatment (Apperley et al., 2002).
For EBF1-PDGFRB, the coding region of
EBF1 is juxtaposed to the C-terminal
region of PDGFRB, preserving the trans-
membrane and kinase domains. It is
predicted that the EBF1 helix-loop-
helix domain mediates homodimerization
(Hagman et al., 1995) and facilitates
constitutive activation of PDGFRB as is
observed with ETV6-PDGFRB (Carroll
et al., 1996). Furthermore, EBF1 is a
transcription factor that plays a majorrole in regulating B cell differentiation (Hagman and Lukin,
2006), and deletions that abolish normal EBF1 function have
been reported inB-lineageALL (Mullighanet al., 2007). The fusion
of EBF1 to PDGFRB is also likely to impair the normal function
of EBF1 and represents a mechanism resulting in PDGFRB
overexpression.
We also identified RANBP2 as a fusion partner for ABL1.
RANBP2 (or NUP358) localizes to the cytoplasmic side of the
nuclear pore complex via interaction with NUP88 and forms
a subcomplex with NUP214 (Bernad et al., 2004). The structural
features of RANBP2 retained in the fusion protein include the
leucine zipper, which is predicted to mediate homodimerization
of RANBP2-ABL1, as observed with RANBP2-ALK in atypicalment. The EPOR locus is inverted so the 50 end is
eft) and exon 8 ofEPOR (chr19:11349946) to IGHV4
, August 14, 2012 ª2012 Elsevier Inc. 161
Figure 6. Phosphosignaling Analysis of Primary Leukemic Blasts Harboring NUP214-ABL1, BCR-JAK2, and STRN3-JAK2 Rearrangements
Cells were untreated or treated with indicated tyrosine kinase inhibitors for 1 hr, and levels of phosphorylated CRKL or tyrosine were assessed by phosphoflow
cytometric analysis. Viable (P1) and single cells (P2) were gated by expression of CD10 and CD19 (P3). Das, dasatinib. Control is secondary antibody alone.
See also Figure S6.
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localization of NUP214-ABL1 to the nuclear pore complex and
interaction with additional nuclear pore proteins is required for
ABL1 kinase activity of this fusion protein (De Keersmaecker
et al., 2008). Thus, we hypothesize that RANBP2-ABL1 may be
activated in a similar manner.
Although a diverse range of kinase lesions are present in Ph-
like ALL, activation of ABL1 and/or JAK/STAT signaling path-
ways is a common mechanism for transformation. The dramatic
improvement in outcome observed in Ph+ B-ALL patients treated
with chemotherapy and imatinib (Schultz et al., 2009) and our
demonstration that Ph-like leukemic cells are sensitive to
currently available TKIs provide a strong rationale to test chemo-
therapy plus TKI treatment in Ph-like ALL patients. At present,
next-generation sequencing is not widely available in diagnostic
laboratories. However, our results indicate that flow cytometric
phosphosignaling analysis can identify Ph-like caseswith activa-
tion of kinase pathways, and in conjunction with flow-cytometric
detection of CRLF2 overexpression (Mullighan et al., 2009a),
may be implemented as a routine diagnostic test. In addition,
the gene expression profile of Ph-like ALL can be used to
design targeted low-density gene expression arrays suitable
for diagnostic use. Although the majority of Ph-like patients do
not harbor known recurring chromosomal rearrangements, initial
screeningmay be performed on all ALL cases. Patients identified
as Ph-like can then undergo additional testing for known genetic
lesions associated with this subtype and be directed to treat-
ment that combines chemotherapy with ABL1, PDGFRB, or162 Cancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc.JAK inhibitors. It is important to note that rare non-Ph-like
patients that harbor kinase alterations (e.g., NUP214-ABL1)
may also benefit from the addition of TKI therapy.
In summary, this study illustrates how the use of genomic
analysis can identify rationale therapeutic targets that drive
tailored treatment and provides a model that can be applied
to a wide range of cancer subtypes to benefit patients with
high-risk disease.
EXPERIMENTAL PROCEDURES
Patients and Samples
Ten Ph-like ALL cases from the COG P9906 high-risk B-ALL study (Bowman
et al., 2011), three cases enrolled on the high-risk COG AALL0232 study
(http://ClinicalTrials.gov Identifier NCT00075725), and two cases treated on
the St. Jude Children’s Research Hospital Total XV (Pui et al., 2009) and
Total XVI protocols (http://ClinicalTrials.gov Identifiers NCT00137111 and
NCT00549848, respectively) were selected for mRNA-seq based on a similar
gene expression profile to BCR-ABL1 ALL, as determined by ROSE clustering
(Harvey et al., 2010b), PAM (Tibshirani et al., 2002), and the availability of
suitable genomic material. All samples were obtained with patient or parent/
guardian provided informed consent under protocols approved by the Institu-
tional Review Board at each COG institution and St. Jude Children’s Research
Hospital. Details on case selection and recurrence are outlined in the Supple-
mental Experimental Procedures.
mRNA-seq and Whole Genome Sequencing
mRNA-seq was performed using amethod similar to that previously described
(Morin et al., 2010). For WGS, Illumina paired-end whole genome shotgun
libraries were prepared from 1 mg of genomic DNA as described (Shah et al.,
2009). Sequencing was performed on the Illumina Genome Analyzer GAIIx
Figure 7. Kinase-Activating Fusions Induce Growth Factor-Independence and Show Response to Tyrosine Kinase Inhibitors
(A) Immunoblot of c-ABL1 and PDGFRB in Ba/F3 (B3) and Arf/ pre-B cells expressing empty vector (MIG), EBF1-PDGFRB, ETV6-PDGFRB, or NUP214-ABL1.
(B and C) Transduced Ba/F3 (B) or Arf/ pre-B cells (C) were grown in the absence of cytokine and cell number was recorded as indicated (left). Ba/F3 or Arf/
pre-B cells were grown in increasing concentrations of imatinib (middle). No cytokine (solid line) or cytokine (dotted line). Error bars represent mean ± SD of three
independent experiments. Cells were untreated or treated with dasatinib for 1 hr, and levels of phosphorylated STAT5 were assessed by phosphoflow cytometric
analysis (right).
(D) Xenograft model of BCR-JAK2 and NUP214-ABL1. Mice were randomized to receive vehicle (40% dimethyl acetamide, 60% propylene glycol; n = 5),
ruxolitinib (30 mg/kg/day; n = 7) or dasatinib (20 mg/kg/day; n = 5). Error bars represent mean ± SEM. **p < 0.001; ***p < 0.0001.
See also Figure S7.
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detection of rearrangements, DNA copy number alterations, and sequence
variations are provided in the Supplemental Experimental Procedures.
RT-PCR, Genomic Mapping, and Sequencing
Putative rearrangements identified by mRNA-seq were validated by RT-PCR
and Sanger sequencing. Leukemic cell RNA was reverse-transcribed using
Superscript III (Life Technologies, Carlsbad, CA, USA) and fusion productsamplified with Phusion HF polymerase (New England Biolabs, Ipswich, MA,
USA). Genomicmapping of theEBF1-PDGFRB andBCR-JAK2 rearrangement
break points was performed using whole genome amplified (Qiagen, Hilden,
Germany) leukemic cell DNA.
Retroviral Constructs, Infection, and Cell Proliferation Assays
The full-length EBF1-PDGFRB fusion was amplified from leukemic cell
cDNA, cloned into pGEM-T-Easy (Promega), and then subcloned into theCancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc. 163
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Kinase-Activating Alterations in High-Risk ALLMSCV-IRES-GFP retroviral vector. Retroviral supernatants containing MSCV-
EBF1-PDGFRB-IRES-GFP, MSCV-ETV6-PDGFRB-IRES-GFP (Carroll et al.,
1996), MSCV-NUP214-ABL1-IRES-GFP (De Keersmaecker et al., 2008), or
MSCV-BCR-ABL1-IRES-GFP (p185) (Williams et al., 2006) were produced
using the ecotropic Phoenix packaging cell line and used to infect murine
hematopoietic progenitor Ba/F3 or primary Arf/ pre-B cells (Williams et al.,
2006). To evaluate factor-independent growth, cells were washed three times,
seeded in triplicate without cytokine, and the cell number was recorded daily
using a Vicell cell counter (Beckman Coulter, Fullerton, CA, USA). Proliferation
rates of each cell line were compared using a linear mixed-effect model with
order-1 autoregressive covariance structure for longitudinal data in the SAS
package (SAS Inc, Cary, NC, USA). Drug sensitivity was assessed using the
CellTiter-Blue Cell Viability Assay (Promega. Madison, WI, USA) in accordance
with the manufacturer’s instructions, and IC50 was determined using nonlinear
regression (GraphPad Prism, La Jolla, CA). Each experiment was performed
three times.
Phosphoflow Analysis and Immunoblotting
To assess signaling within leukemic samples and cell lines, intracellular phos-
phoflow cytometric analysis were performed as previously described (Kotecha
et al., 2008). Briefly, cryopreserved patient samples were thawed, or cells in
culture were harvested at 1 3 106 cells per tube and treated with the TKIs
imatinib (Novartis, Basel, Switzerland), dasatinib (Bristol Myers Squibb,
New York, NY, USA), XL228, or XL019 (Exelixis, South San Francisco, CA,
USA) for 1 hr. Cells were fixed, permeabilized, and stained with either anti-
phospho-tyrosine-4G10 (Upstate, now EMD Millipore Corporation, Billerica,
MA, USA), anti-pAKT (S573), anti-pCRKL (Y207), anti-pERK1/2 (T202/Y204),
or anti-pSTAT5 (Y694; Cell Signaling Technology, Danvers, MA, USA) and
then Alexa Fluor 647 conjugated anti-rabbit or Pacific Blue conjugated anti-
mouse IgG secondary antibodies (Life Technologies, Carlsbad, CA, USA).
Cellular fluorescence data were collected on an LSR II flow cytometer (BD
Biosciences, Franklin Lakes, NJ, USA) using DIVA software (BD Biosciences)
and analyzed with FlowJo (Tree Star, Ashland, OR, USA). For immunoblotting,
cells were lysed in RIPA buffer, subjected to SDS-PAGE, and probed with anti-
phospho-tyrosine-4G10 (Upstate [now EMD Millipore Corporation]), anti-
c-ABL, anti-PDGFRB, and anti-Actin (Santa Cruz Biotechnology, Santa
Cruz, CA, USA).
Xenograft Models
Xenograft models of case PAKYEP (BCR-JAK2) and PAKVKK (NUP214-
ABL1) were established as previously described with modifications (Teachey
et al., 2006). Primary leukemia cells from bone marrow were intravenously
injected into the tail vein of NSG mice (107 cells/mouse). Following engraft-
ment (>5% human CD19+/45+ blasts in peripheral blood), BCR-JAK2 mice
were randomized to receive ruxolitinib (30 mg/kg/day; Incyte, Wilmington,
DE, USA) or vehicle (40% dimethyl acetamide, 60% propylene glycol) by
continuous subcutaneous infusion using implanted mini-osmotic pumps
(Alzet). For NUP214-ABL1 mice, dasatinib (20 mg/kg; Bristol Myers Squibb)
or vehicle (10% citric acid in 80 mM sodium citrate) was given 5 days a week
by oral gavage. Disease burden was assessed weekly by flow cytometric
determination of human CD19+/45+ blast count in peripheral blood, using
CountBright beads (Invitrogen, Carlsbad, CA, USA). Deaths within 72 hr of
pump placement were considered secondary to anesthesia or surgery, and
these mice were censored at the time of death. All experiments were con-
ducted on protocols approved by the Institutional Animal Care and Use
Committee and Institutional Review Board of The Children’s Hospital of
Philadelphia.
ACCESSION NUMBERS
The sequence data and SNP microarray data have been deposited in the
database of genotypes and phenotypes (dbGAP, http://www.ncbi.nlm.nih.
gov/gap) database under the accession number phs000218.v1.p1. The
gene expression data for COG P9906 has been deposited at the National
Center for Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO), accession GSE11877. The gene expression data without metadata
for COG AALL0232 is deposited at the National Cancer Institute caArray site
(https://array.nci.nih.gov/caarray/project/EXP-578). The NCBI Genbank data-164 Cancer Cell 22, 153–166, August 14, 2012 ª2012 Elsevier Inc.base accession number for the EBF1-PDGFRB sequence reported in this
paper is JN003579.
SUPPLEMENTAL INFORMATION
Supplemental information includes seven figures, nine tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
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